PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33094916-6	2020	The most prioritized of them (i.e., Plcb1 and Prkcb in PFC, and Dnm2 and Lrrk2 in striatum) were associated with synaptic neuroplasticity, a neuroadaptation associated with excessive ethanol drinking.	Ethanol	183-190	dynamin 2	Mus musculus	64-68
34371181-6	2022	Systemic injection of antisense oligonucleotides targeting Dnm2 (Dynamin 2) that codes for dynamin 2, a BIN1 binding partner regulating membrane fission and mutated in other forms of centronuclear myopathy, improved muscle force and normalized the histological Bin1mck-/- phenotypes within 5 weeks.	Oligonucleotides	32-48	dynamin 2	Mus musculus	59-63
34371181-6	2022	Systemic injection of antisense oligonucleotides targeting Dnm2 (Dynamin 2) that codes for dynamin 2, a BIN1 binding partner regulating membrane fission and mutated in other forms of centronuclear myopathy, improved muscle force and normalized the histological Bin1mck-/- phenotypes within 5 weeks.	Oligonucleotides	32-48	dynamin 2	Mus musculus	65-74
34371181-6	2022	Systemic injection of antisense oligonucleotides targeting Dnm2 (Dynamin 2) that codes for dynamin 2, a BIN1 binding partner regulating membrane fission and mutated in other forms of centronuclear myopathy, improved muscle force and normalized the histological Bin1mck-/- phenotypes within 5 weeks.	Oligonucleotides	32-48	dynamin 2	Mus musculus	91-100
33618608-11	2021	An increased association with LAMP1-positive structures was also observed for clathrin and DNM2/dynamin 2, which are important effectors of ALR recruited by phospholipids.	Phospholipids	157-170	dynamin 2	Mus musculus	91-95
33618608-11	2021	An increased association with LAMP1-positive structures was also observed for clathrin and DNM2/dynamin 2, which are important effectors of ALR recruited by phospholipids.	Phospholipids	157-170	dynamin 2	Mus musculus	96-105
33500730-10	2021	Furthermore, an endocytosis inhibitor targeting dynamin-2 preferentially suppressed the uptake of sEV by primary MM cells ex vivo and enhanced the anti-MM effects of bortezomib in vitro and in a mouse model.	Bortezomib	166-176	dynamin 2	Mus musculus	48-57
28466468-1	2017	In a dominant mouse ethylnitrosurea mutagenesis screen for genes regulating erythropoiesis, we identified a pedigree with a novel microcytic hypochromia caused by a V235G missense mutation in Dynamin 2 (Dnm2).	ethylnitrosurea	20-35	dynamin 2	Mus musculus	192-201
32514412-6	2020	Decreasing Dnm2 by genetic cross with Dnm2 +/- mice or by antisense oligonucleotides blocked or postponed disease progression and resulted in an increase in circulating myostatin.	Oligonucleotides	68-84	dynamin 2	Mus musculus	11-15
31308798-8	2019	In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated.	Memantine	24-33	dynamin 2	Mus musculus	156-160
30451843-7	2018	Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue.	Tamoxifen	0-9	dynamin 2	Mus musculus	73-77
30291191-6	2018	injections of antisense oligonucleotides targeting Dnm2 were administered to Dnm2 RW/+mice for 5 wk.	Oligonucleotides	24-40	dynamin 2	Mus musculus	51-55
28466468-3	2017	The V235G mutation lies within a crucial GTP nucleotide-binding pocket of Dnm2, and resulted in defective GTPase activity and incompatibility with life in the homozygous state.	gtp nucleotide	41-55	dynamin 2	Mus musculus	74-78
28466468-4	2017	Dnm2 is an essential mediator of clathrin-mediated endocytosis, which is required for the uptake of transferrin (Tf) into red cells for incorporation of haem.	Heme	153-157	dynamin 2	Mus musculus	0-4
25421092-0	2015	The Dynamin 2 inhibitor Dynasore affects the actin filament distribution during mouse early embryo development.	N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	24-32	dynamin 2	Mus musculus	4-13
26791826-7	2016	DNM2 overexpression decreased nitrite production (index of NO) in both COS7 and mIMCD-3 cells by 50-75%.	Nitrites	30-37	dynamin 2	Mus musculus	0-4
26791826-8	2016	mIMCD-3 cells treated with a panel of dynamin inhibitors or DNM2 siRNA displayed increased nitrite production.	Nitrites	91-98	dynamin 2	Mus musculus	60-64
26791826-13	2016	We propose that DNM2 acts as a "break" to prevent excess or potentially toxic NO levels under high-salt conditions.	Salts	99-103	dynamin 2	Mus musculus	16-20
26413867-3	2015	Dynamin 2 deletion in beta cells caused glucose intolerance and substantial reduction of the second phase of glucose-stimulated insulin secretion (GSIS); however, mutant beta cells still maintained abundant insulin granules, with no signs of cell surface expansion.	Glucose	40-47	dynamin 2	Mus musculus	0-9
26413867-3	2015	Dynamin 2 deletion in beta cells caused glucose intolerance and substantial reduction of the second phase of glucose-stimulated insulin secretion (GSIS); however, mutant beta cells still maintained abundant insulin granules, with no signs of cell surface expansion.	Glucose	109-116	dynamin 2	Mus musculus	0-9
28589938-0	2017	Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.	Oligonucleotides	10-25	dynamin 2	Mus musculus	35-39
28589938-4	2017	Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice efficiently reduces DNM2 protein level in muscle and prevents the myopathy from developing.	Oligonucleotides	54-70	dynamin 2	Mus musculus	39-43
28589938-4	2017	Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice efficiently reduces DNM2 protein level in muscle and prevents the myopathy from developing.	Oligonucleotides	54-70	dynamin 2	Mus musculus	115-119
28589938-4	2017	Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice efficiently reduces DNM2 protein level in muscle and prevents the myopathy from developing.	Oligonucleotides, Antisense	72-76	dynamin 2	Mus musculus	39-43
28589938-4	2017	Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice efficiently reduces DNM2 protein level in muscle and prevents the myopathy from developing.	Oligonucleotides, Antisense	72-76	dynamin 2	Mus musculus	115-119
27840081-0	2017	Hepatic Stellate Cell Selective Disruption of Dynamin-2 GTPase Increases Murine Fibrogenesis through Up-Regulation of Sphingosine-1 Phosphate-Induced Cell Migration.	sphingosine 1-phosphate	118-141	dynamin 2	Mus musculus	46-55
27840081-2	2017	A point mutation converting lysine 44 of Dyn2 to alanine (Dyn2K44A) disrupts its GTPase activity.	Lysine	28-34	dynamin 2	Mus musculus	41-45
27840081-2	2017	A point mutation converting lysine 44 of Dyn2 to alanine (Dyn2K44A) disrupts its GTPase activity.	Alanine	49-56	dynamin 2	Mus musculus	41-45
27870637-0	2016	Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy.	Calcium	0-7	dynamin 2	Mus musculus	56-65
27870637-4	2016	Heterozygous (HTZ) KI-Dnm2 mice progressively develop muscle atrophy, impairment of contractile properties, histopathological abnormalities, and elevated cytosolic calcium concentration.	Calcium	164-171	dynamin 2	Mus musculus	22-26
27870637-10	2016	Our results highlight the first pathomechanism which may explain the spatial muscle involvement occurring in DNM2-related CNM and open the way toward development of a therapeutic approach to normalize calcium content.	Calcium	201-208	dynamin 2	Mus musculus	109-113
27802433-7	2016	RESULTS: Inhibition of Drp1 and Dynamin 2 protected against mitochondrial fragmentation, maintained DeltaPsim, attenuated cellular ROS production and limited apoptosis.	Reactive Oxygen Species	131-134	dynamin 2	Mus musculus	32-41
27802433-8	2016	Moreover, Lv5-shRNA mediated knockdown of Dynamin 2 alleviated mitochondrial fragmentation, and reduced both ROS production and oxidative stress-induced apoptosis.	Reactive Oxygen Species	109-112	dynamin 2	Mus musculus	42-51
27802433-10	2016	CONCLUSIONS: Oxidative stress-induced apoptosis and ROS production are attenuated by not only Drp1 inhibition but also Dynamin 2 inhibition, implicating Dynamin 2 as a mediator of oxidative stress in cardiomyocytes.	Reactive Oxygen Species	52-55	dynamin 2	Mus musculus	153-162
15545517-10	2004	CONCLUSIONS: Our data demonstrated that dynamin-2 at least partially regulated oxLDL-induced apoptosis of VSMC by participating in 2 independent pathways: the oxLDL endocytotic pathway and the p53 pathway.	vsmc	106-110	dynamin 2	Mus musculus	40-49
19563849-9	2009	Using siRNA to Scamp2 did not change glucose stimulated insulin release but siRNA to Dynamin2 and dominant negative Dynamin2 (Dyn K44A) inhibited glucose stimulated insulin release and abolished the response to enterostatin.	Glucose	146-153	dynamin 2	Mus musculus	116-124
19563849-10	2009	This suggests enterostatin inhibits glucose stimulated insulin release in pancreatic beta cells through down regulation of Dynamin2.	Glucose	36-43	dynamin 2	Mus musculus	123-131
17785912-5	2007	Immunoelectron microscopy disclosed that both amphiphysin 1 and dynamin 2 were localized on TBC membrane.	tbc	92-95	dynamin 2	Mus musculus	64-73
17785912-10	2007	These results suggest that amphiphysin 1 and dynamin 2 are involved in TBC formation and spermatid release at Sertoli cells.	tbc	71-74	dynamin 2	Mus musculus	45-54
15765525-8	2005	Results indicate that etorphine induced dose-dependent regulation of muOR density, DYN-2 proteins, and mRNA abundance in mouse spinal cord.	Etorphine	22-31	dynamin 2	Mus musculus	83-88
19479281-9	2009	Ultrastructural analysis with a quick-freezing and deep-etching method confirmed these findings and revealed the existence of distinct Dyn2-bound microfilaments in close association with DV membranes.	dv	187-189	dynamin 2	Mus musculus	135-139
17349996-12	2007	Furthermore, etorphine increased spinal dynamin-2 abundance, while oxycodone did not produce any significant change in dynamin-2 abundance.	Etorphine	13-22	dynamin 2	Mus musculus	40-49
12872295-9	2003	NTX increased DAMGO analgesic potency (3.1-fold) 24 h following NTX treatment, while there was no effect at 192 h. NTX decreased protein and mRNA abundance of GRK-2 (-32%; -48%) and DYN-2 (-25%; -29%) in spinal cord at 0 h. At 192 h following 8-day NTX treatment, GRK-2 protein and mRNA were at control levels, while DYN-2 protein remained decreased (-31%) even though DYN-2 mRNA had returned to control levels.	Naltrexone	0-3	dynamin 2	Mus musculus	182-187
15363980-7	2004	Continuous (7-8 days) s.c. infusions of naloxone (5 mg/kg/day) or naltrexone (15 mg s.c. implant pellet) increased mu-opioid receptor density in radioligand binding assays (approximately +80%) in mouse spinal cord and down-regulated dynamin-2 abundance (approximately -30%), but had no effect on the abundance of immunoreactive mu-opioid receptor.	Naloxone	40-48	dynamin 2	Mus musculus	233-242
15363980-7	2004	Continuous (7-8 days) s.c. infusions of naloxone (5 mg/kg/day) or naltrexone (15 mg s.c. implant pellet) increased mu-opioid receptor density in radioligand binding assays (approximately +80%) in mouse spinal cord and down-regulated dynamin-2 abundance (approximately -30%), but had no effect on the abundance of immunoreactive mu-opioid receptor.	Naltrexone	66-76	dynamin 2	Mus musculus	233-242
15363980-8	2004	Continuous (7 days) s.c. infusion of etorphine (200 microg/kg/day) decreased immunoreactive mu-opioid receptor (approximately -35%) and [3H] DAMGO binding (approximately -30%), and concurrently increased dynamin-2 abundance (approximately +40%).	Etorphine	37-46	dynamin 2	Mus musculus	204-213
15363980-13	2004	Taken together, these results suggest that etorphine-induced down-regulation may depend upon mu-opioid receptor degradation and changes in dynamin-2-mediated receptor trafficking.	Etorphine	43-52	dynamin 2	Mus musculus	139-148
12872295-9	2003	NTX increased DAMGO analgesic potency (3.1-fold) 24 h following NTX treatment, while there was no effect at 192 h. NTX decreased protein and mRNA abundance of GRK-2 (-32%; -48%) and DYN-2 (-25%; -29%) in spinal cord at 0 h. At 192 h following 8-day NTX treatment, GRK-2 protein and mRNA were at control levels, while DYN-2 protein remained decreased (-31%) even though DYN-2 mRNA had returned to control levels.	Naltrexone	0-3	dynamin 2	Mus musculus	317-322
12872295-9	2003	NTX increased DAMGO analgesic potency (3.1-fold) 24 h following NTX treatment, while there was no effect at 192 h. NTX decreased protein and mRNA abundance of GRK-2 (-32%; -48%) and DYN-2 (-25%; -29%) in spinal cord at 0 h. At 192 h following 8-day NTX treatment, GRK-2 protein and mRNA were at control levels, while DYN-2 protein remained decreased (-31%) even though DYN-2 mRNA had returned to control levels.	Naltrexone	0-3	dynamin 2	Mus musculus	317-322
12435815-4	2002	Therefore, we examined etorphine and morphine effects on regulation of GRK-2 and DYN-2 in mouse spinal cord.	Etorphine	23-32	dynamin 2	Mus musculus	81-86
12957235-2	2003	In previous studies, naltrexone treatment produced an increase in muOR density accompanied by decreases in GRK-2 and DYN-2 protein abundance.	Naltrexone	21-31	dynamin 2	Mus musculus	117-122
12435815-4	2002	Therefore, we examined etorphine and morphine effects on regulation of GRK-2 and DYN-2 in mouse spinal cord.	Morphine	37-45	dynamin 2	Mus musculus	81-86
12435815-12	2002	Etorphine increased ( approximately 70%) DYN-2 protein abundance and decreased its mRNA (31%), whereas it had no effect on GRK-2 protein and mRNA abundance.	Etorphine	0-9	dynamin 2	Mus musculus	41-46
12098583-8	2002	Naltrexone treatment was associated with a significant 36% decrease in GRK-2 and 30% decrease in dynamin-2 abundance in spinal cord.	Naltrexone	0-10	dynamin 2	Mus musculus	97-106
12419186-5	2002	When expressed in cultured cells, a dynamin2 mutant with decreased affinity for GTP decreased actin dynamics within the cortical actin network.	Guanosine Triphosphate	80-83	dynamin 2	Mus musculus	36-44
12419186-9	2002	Dynamin2 promoted the association of actin filaments nucleated by Arp2/3 complex and cortactin with phosphatidylinositol 4,5-bisphosphate (PIP2)-containing lipid vesicles.	Phosphatidylinositol 4,5-Diphosphate	100-137	dynamin 2	Mus musculus	0-8
12419186-9	2002	Dynamin2 promoted the association of actin filaments nucleated by Arp2/3 complex and cortactin with phosphatidylinositol 4,5-bisphosphate (PIP2)-containing lipid vesicles.	Phosphatidylinositol 4,5-Diphosphate	139-143	dynamin 2	Mus musculus	0-8